Predict your next investment

Vizient company logo
Corporation
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing / Business Performance Management
vizientinc.com

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Partners & Customers

10

Service Providers

1

About Vizient

Vizient provides analytics and advisory services to the healthcare industry. Its customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute health care providers.

Vizient Headquarter Location

290 East John Carpenter Freeway

Irving, Texas, 75062,

United States

972 830 0000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vizient

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Vizient in 2 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

H

Health IT

924 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

Vizient Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Vizient Rank

Latest Vizient News

'Cascade of Impact': COVID-19 surge again threatens patient access to maintenance drugs

Sep 17, 2021

ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio In a disturbing repeat of last year’s run on hydroxychloroquine, U.S. health care systems are scrambling to maintain tocilizumab access for rheumatology patients following the drug’s emergency use authorization for COVID-19 and the surge in delta variant cases. Between June 24 and August 13, demand for tocilizumab (Actemra, Genentech) in the COVID-19 setting drove a 279% increase in requests for the IV formulation of the drug, according to data from Vizient, a member-driven health care performance improvement company. Further data showed a simultaneous reduction in fill rates of IV tocilizumab prescriptions by hospitals from 99% to 45%. “We tend to see this in extreme critical care situations,” Steven Lucio, PharmD, told Healio Rheumatology. “The loss of one product leads to the next one going short, a cascade of impact. I am not saying that that is going happen, but if you have even one patient who has difficulty getting treatment, it is a problem.” Source: Adobe Stock The impact of this trend on the rheumatology community could be severe. Patients with conditions ranging from rheumatoid arthritis and giant cell arteritis to polyarticular and systemic juvenile idiopathic arthritis, along with cytokine release syndrome , all benefit from tocilizumab. According to a statement from manufacturer Genentech, the issue is ongoing beyond the dates of the Vizient study. “This new wave of the pandemic has led to Genentech experiencing an unprecedented demand for Actemra IV — well over 400% of pre-COVID levels over the last 2 weeks alone and it continues to increase,” the company noted. Steven Lucio All of this comes on the heels of a number of shortages related to the pandemic, from personal protective equipment and ventilators at the outset to hydroxychloroquine through the heart of 2020 , according to Steven Lucio, PharmD, vice president of pharmacy solutions at Vizient. “This has been part of the collateral damage of COVID,” he told Healio Rheumatology. “Now we are starting to feel the same pressure with tocilizumab, with the supply not being able to keep up with the demand. It is a challenge for rheumatologists.” The hope is that the players in this scenario — rheumatologists, pharmacists and hospital administrators among them — have learned from past mistakes and are equipped to manage drug inventories moving more successfully forward. But understanding the scope and nature of the shortages, and how to best mitigate them, is critical. Cascading Effects If tocilizumab was the only drug impacted, it would be one issue; but the problem is bigger than that. Findings from Vizient showed that demand for the tocilizumab alternative baricitinib (Olumiant, Eli Lilly & Co.) has increased 1,421% over the same time period, leading to a drop in fill rates from 99% to 89%. Also, as might be expected, demand for remdesivir (Veklury, Gilead Sciences) increased 632% and dexamethasone demand increased 47.5% over the period between June and August studied by the Vizient group. “The NIH said recently that it is not possible to get Actemra or Olumiant,” Lucio said. “This is all part of the hardship that the rheumatology community has had to endure. It really highlights the tangential effects a pandemic or natural disaster can have on vulnerable populations.” While Lucio believes that shortages of all the aforementioned drugs are unlikely to be widespread enough to leave most or all rheumatology patients without their medications, he urged ongoing vigilance. “We tend to see this in extreme critical care situations,” he said. “The loss of one product leads to the next one going short, a cascade of impact. I am not saying that that is going happen, but if you have even one patient who has difficulty getting treatment, it is a problem.” However, there is hope in the current go-round of drug shortages . A Genentech spokesperson told Healio Rheumatology that manufacturers are well aware of the situation. “We have begun receiving scheduled replenishments of Actemra in the U.S. and anticipate additional replenishments of all SKUs of Actemra IV and subcutaneous formulations,” the statement read. However, given that the use of the drug in COVID-19 is unpredictable and based on the changing course of the pandemic, the company stressed that availability may vary. “Patients interested in subcutaneous Actemra should speak with their doctor,” the statement noted, and then offered some practical advice for practitioners. “For the most up-to-date information on product availability for Actemra IV and/or subcutaneous formulations, hospitals and practices should contact their authorized distributors.” Tracing History While the natural inclination may be to look to the hydroxychloroquine debacle for clues as to how the tocilizumab shortage will unfold, Lucio suggested that comparing these “apples to oranges” may not be so helpful. “We certainly hope that what we learned in the earlier part of the pandemic will help us with what is happening with tocilizumab,” he said. “Many organizations had to deal with these supply challenges, and we have certainly become very astute at trying to closely manage inventories, largely by closely managing the patients who need those drugs.” However, the future of tocilizumab availability for rheumatology patients depends on a few key factors. “One depends on if we are able to change trend lines for vaccinations,” Lucio said. “Or, failing that, if we can somehow bring about a diminishing amount of COVID cases altogether.” That, obviously, is a big if. With that in mind, experts like those at Vizient and manufacturers like Genentech are focused on avoiding shortages for demanding populations, like patients with RA. But the way of avoiding these shortages — along with the attendant interruptions or delays in treatment that could lead to worsening disease outcomes — is imperfect, according to Lucio. “We are hearing from more and more of our members that patients with RA who get the IV product are moving to the subcutaneous formulation of tocilizumab,” he said. “This, obviously, is not ideal.” The reason for this is that if a patient is well-maintained on any therapy, shifting gears can be problematic, even if that shift is merely in the delivery of the drug. “There are considerable efforts being made with inventory to make sure things don’t fall off the cliff,” Lucio said. Preventing Shortages Lucio offered some hardboiled advice to rheumatologists to ensure their patients can get their tocilizumab and other prescriptions filled. “You need to have your pharmacy on speed dial,” he said. “You need to understand what strategies have been put in place to manage that inventory.” A “bidirectional dialogue” between physician and health system about patient load and the inventory of drugs is also necessary. “Your pharmacy can work with wholesalers, they can work directly with the drug company itself to bring inventory together,” he said. “But none of this will help patients if you don’t know about these avenues and protocols.” The benefits of a knowledgeable and proactive rheumatologist can be felt by patients. “Of course, if you can keep them on the formulation that is working for them, that will be beneficial,” Lucio said. “But changes in therapy can also include changes in copays or out-of-pocket expenses. Patients know that their provider is working the pharmacy or other players to avoid disruptions in their care.” In short, every rheumatologist should have a roadmap in place for keeping their patients on their treatment. “If their care is, in fact, disrupted, you need to know the next step in the plan,” he said, and stressed one other consideration. “The protocols are different from health system to health system, so you should make sure to understand the protocols where you are practicing.” Tocilizumab Utility in COVID-19 If there is an elephant in the room, it is the extent to which tocilizumab, baricitinib or other drugs in the rheumatology armamentarium can have efficacy in COVID-19. This unknown factor could have a huge impact on the extent and nature of shortages going forward. “The emergency use authorization was based on four randomized, controlled studies that investigated the safety and efficacy of Actemra in more than 5,500 hospitalized patients with COVID-19,” according to the Genentech statement. The RECOVERY study , published in the Lancet, was led by researchers in the United Kingdom and included more than 4,000 hospitalized COVID-19 patients with hypoxia and systemic inflammation. Results showed that tocilizumab improved survival and other clinical outcomes and did not depend on the amount of respiratory support. Moreover, tocilizumab may increase the clinical benefit of systemic corticosteroids in these patients. Salama and colleagues published findings from the EMPACTA study in the New England Journal of Medicine. “In hospitalized patients with COVID-19 pneumonia who were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, but it did not improve survival,” the researchers concluded. “No new safety signals were identified.” Rosas and colleagues published findings for the COVACTA trial in the New England Journal of Medicine. They found that among hospitalized patients with severe COVID-19 pneumonia, tocilizumab failed to significantly improve clinical status or lower mortality over placebo at 28 days. While results of the REMDACTA study have not yet been published in a peer-reviewed journal, early data indicated that a combination of tocilizumab and remdesivir may not shorten hospital stay length. “The results of these studies suggest that Actemra may improve outcomes in patients receiving corticosteroids and requiring supplemental oxygen or breathing support,” the Genentech spokesperson told Healio Rheumatology. “There have been no new safety signals identified for Actemra in any of these studies.” These early findings suggest that there may be “more real clinical hope” for tocilizumab than there ever was for hydroxychloroquine, according to Lucio. “There does seem to be a consistency of this medication helping people who are critically ill,” he said. However, further studies are necessary to elucidate the extent to which tocilizumab can lower mortality or reduce the length of hospital stay. Regarding the utility of baricitinib in COVID-19, Lucio was similarly cautious. “It seems like a drug that hopefully helps beyond just wishful thinking,” he said. “But we do not know for sure.” In the meantime, Lucio urged rheumatologists to pay attention to the FDA, CDC and the American College of Rheumatology for guidance on all things pertaining to patient management, including trends in drug shortages . “Given all that we have been through, these organizations have become more adept at updating guidelines and developing best practices more rapidly,” Lucio said. “There is a general feeling that we know better how to disseminate information to help clinicians. There is also not as much of a spiral of uncertainty as there was.” While rheumatologists and their patients can take comfort in this, if there is a question that remains, it is the extent to which delta, mu and other COVID-19 variants will impact drug shortages. Unfortunately, even experts like Lucio, who have been studying the trends and publishing data, are unable to predict the future. The only real way to prevent shortages is to produce more of the drugs in question. “Genentech and Roche are working as quickly as possible to expedite replenishments and increase manufacturing capacity and supply, including through active collaboration with external partners,” the Genentech statement read. “Genentech has implemented new distribution strategies for hospital and clinic customers to enable access for the greatest number of patients, as supply permits.” Lucio underscored this point. “People who manage supply chain are spending days and nights to prevent and mitigate as much of the patient component as possible,” he said. References:

Vizient Investments

2 Investments

Vizient has made 2 investments. Their latest investment was in Panda Health as part of their Seed on August 8, 2021.

CBI Logo

Vizient Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/24/2021

Seed

Panda Health

Yes

4

7/12/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/24/2021

7/12/2021

Round

Seed

Series B

Company

Panda Health

Subscribe to see more

Amount

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

4

10

Vizient Portfolio Exits

1 Portfolio Exit

Vizient has 1 portfolio exit. Their latest portfolio exit was Vizient - Contract Labor Management (CLM) Business Unit on August 09, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/9/2021

Divestiture

1

Date

8/9/2021

Exit

Divestiture

Companies

Valuation

Acquirer

Sources

1

Vizient Acquisitions

3 Acquisitions

Vizient acquired 3 companies. Their latest acquisition was Intalere on November 05, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/5/2020

Corporate Minority

Acquired

2

2/15/2016

Subscribe to see more

$99M

Subscribe to see more

10

2/15/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/5/2020

2/15/2016

2/15/2016

Investment Stage

Corporate Minority

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

Total Funding

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Sources

2

10

10

Vizient Partners & Customers

10 Partners and customers

Vizient has 10 strategic partners and customers. Vizient recently partnered with VitalTech on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/18/2021

Vendor

VitalTech

United States

06:58 ET VitalTech Announces Agreement with Vizient for its Market Leading Virtual Care Solutions

VitalTech 's contract with Vizient , Inc. went into effect on August 1 , 2021 .

1

7/28/2021

Client

Carrum Health

United States

07:00 ET Carrum Health and Vizient Collaborate to Accelerate National Rollout of Bundled Payment Centers of Excellence Platform

`` Carrum Health continuously seeks to deliver the most innovative and high-quality programs and we are looking forward to the next evolution of their offerings made possible through their strategic partnership with Vizient , Inc. . ''

1

7/15/2021

Vendor

Integra

United States

Integra Receives Innovative Technology Contract from Vizient

`` We are pleased that Vizient has selected SurgiMend as an innovative technology , '' said Dean Sollami , vice president of sales at Integra .

1

6/29/2021

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/19/2021

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/18/2021

7/28/2021

7/15/2021

6/29/2021

5/19/2021

Type

Vendor

Client

Vendor

Vendor

Vendor

Business Partner

VitalTech

Carrum Health

Integra

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

06:58 ET VitalTech Announces Agreement with Vizient for its Market Leading Virtual Care Solutions

VitalTech 's contract with Vizient , Inc. went into effect on August 1 , 2021 .

07:00 ET Carrum Health and Vizient Collaborate to Accelerate National Rollout of Bundled Payment Centers of Excellence Platform

`` Carrum Health continuously seeks to deliver the most innovative and high-quality programs and we are looking forward to the next evolution of their offerings made possible through their strategic partnership with Vizient , Inc. . ''

Integra Receives Innovative Technology Contract from Vizient

`` We are pleased that Vizient has selected SurgiMend as an innovative technology , '' said Dean Sollami , vice president of sales at Integra .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Vizient Service Providers

1 Service Provider

Vizient has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired Unit

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acquired Unit

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Vizient Team

11 Team Members

Vizient has 11 team members, including current Senior Vice President, John Becker.

Name

Work History

Title

Status

John Becker

Senior Vice President

Current

Aaron Gerber

President

Former

Jody Hatcher

President

Former

ROBERT CHAPEL

Chief Financial Officer

Former

Peter Csapo CPA

Chief Financial Officer, Chief Information Officer, Senior Vice President

Former

Name

John Becker

Aaron Gerber

Jody Hatcher

ROBERT CHAPEL

Peter Csapo CPA

Work History

Title

Senior Vice President

President

President

Chief Financial Officer

Chief Financial Officer, Chief Information Officer, Senior Vice President

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.